Sign Up for a Free Account
  • Updated 09.16.2021
  • Released 12.30.2005
  • Expires For CME 09.16.2024



Historical note and terminology

Pregabalin is chemically related to the antiepileptic drug gabapentin and is a successor to it for management of neuropathic pain as well as an adjunct therapy for the management of partial onset seizures. Gabapentin, a GABA receptor agonist, is an approved as add-on therapy for intractable partial seizures in adults. Clinical trials of pregabalin started in 2000. It was approved by the FDA for treating diabetic neuropathy and postherpetic neuralgia in 2004 and for fibromyalgia in 2007.

In 2005 the Drug Enforcement Administration placed pregabalin into Schedule V of the Controlled Substances Act. Because of this rule, the regulatory controls and criminal sanctions of Schedule V will be applicable to the manufacture, distribution, dispensing, importation and exportation of pregabalin and products containing pregabalin. In 2012, the manufacturer paid a settlement for misleading promotion of the drug for off-label indications.

This is an article preview.
Start a Free Account
to access the full version.

  • Nearly 3,000 illustrations, including video clips of neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of neurology in 1,200 comprehensive articles.

  • Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660



ISSN: 2831-9125